Monopar Therapeutics Inc. presented new data on the long-term neurological efficacy and safety of its investigational therapy ALXN1840 (tiomolybdate choline) for Wilson disease at the 150th American Neurological Association (ANA) Annual Meeting on September 14, 2025.
The presentation, based on an abstract accepted with distinction, focused on the sustained improvement of neurological symptoms in Wilson disease patients treated with tiomolybdate choline. This data further supports the potential of ALXN1840 as a therapeutic option.
The American Neurological Association Annual Meeting is a key forum for presenting advancements in neurological research. The detailed findings contribute to the growing body of evidence for ALXN1840 as Monopar prepares for its New Drug Application filing.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.